There is an unmet
need in clinical point-of-care (POC) cancer diagnostics
for early state disease detection, which would greatly increase patient
survival rates. Currently available analytical techniques for early
stage cancer diagnosis do not meet the requirements for POC of a clinical
setting. They are unable to provide the high demand of multiplexing,
high-throughput, and ultrasensitive detection of biomarkers directly
from low volume patient samples (“liquid biopsy”). To
overcome these current technological bottle-necks, herein we present,
for the first time, a bottom-up fabrication strategy to develop plasmonic
nanoantenna-based sensors that utilize the unique localized surface
plasmon resonance (LSPR) properties of chemically synthesized gold
nanostructures, gold triangular nanoprisms (Au TNPs), gold nanorods
(Au NRs), and gold spherical nanoparticles (Au SNPs). Our Au TNPs,
NRs, and SNPs display refractive index unit (RIU) sensitivities of
318, 225, and 135 nm/RIU respectively. Based on the RIU results, we
developed plasmonic nanoantenna-based multiplexing and high-throughput
biosensors for the ultrasensitive assay of microRNAs. MicroRNAs are
directly linked with cancer development, progression, and metastasis,
thus they hold promise as next generation biomarkers for cancer diagnosis
and prognosis. The developed biosensors are capable of assaying five
different types of microRNAs at an attomolar detection limit. These
sets of microRNAs include both oncogenic and tumor suppressor microRNAs.
To demonstrate the efficiency as a POC cancer diagnostic tool, we
analyzed the plasma of 20-bladder cancer patients without any sample
processing steps. Importantly, our liquid biopsy-based biosensing
approach is capable of differentiating healthy from early (“non-metastatic”)
and late (“metastatic”) stage cancer with a p value <0.0001. Further, receiver operating characteristic
analysis shows that our biosensing approach is highly specific, with
an area under the curve of 1.0. Additionally, our plasmonic nanoantenna-based
biosensors are regenerative, allowing multiple measurements using
the same biosensors, which is essential in low- and middle-income
countries. Taken together, our multiplexing and high-throughput biosensors
have the unmatched potential to advance POC diagnostics and meet global
needs for early stage detection of cancer and other diseases (e.g.,
infectious, autoimmune, and neurogenerative diseases).